Richard Lambert, MD
Pulmonary Disease · Lewiston, IDNPI 1659318798
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by GSK at 36.8% of the total. Reporting peaked in 2019 at $368 and has fallen 60.7% since, to $145 in 2023. That places this record below the midpoint for pulmonary disease clinicians in ID, where the typical reported total is $479.
Across 25 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$208
- Pulmonx Corporation$145
- AstraZeneca$94
- Grifols USA, LLC$44
- Sunovion Pharmaceuticals Inc.$33
- Mylan Specialty L.p.$16
- plus $26 from 2 others
What the payments were for
- Food & beverage$565100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $208 |
| Pulmonx Corporation | 2 | $145 |
| AstraZeneca | 5 | $94 |
| Grifols USA, LLC | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 3 | $33 |
| Mylan Specialty L.p. | 1 | $16 |
| Insmed, Inc. | 1 | $14 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$565 in reported general payments places this provider in the 50th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Lewiston
- Todd HoopmanCoeur D Alene$76K
- Allen SalemIdaho Falls$44K
- Mark RasmusBoise$44K
- Shawn FrenchTwin Falls$26K
- Karen MillerMeridian$12K
- Wesley PidcockNampa$12K
- Norman EastBoise$11K
- Jordan CormierIdaho Falls$9K
- Oleg KouskovMeridian$8K
- Derek LindermanBoise$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.